Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Author(s) -
Atsushi Hiraoka,
Takashi Kumada,
Masatoshi Kudo,
Masashi Hirooka,
Kunihiko Tsuji,
Ei Itobayashi,
Kazuya Kariyama,
Toru Ishikawa,
Kazuto Tajiri,
Hironori Ochi,
Toshifumi Tada,
Hidenori Toyoda,
Kazuhiro Nouso,
Kouji Joko,
Hideki Kawasaki,
Yoichi Hiasa,
Kojiro Michitaka
Publication year - 2017
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000452846
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , bilirubin , liver function , hepatology , cohort , indocyanine green , guideline , proportional hazards model , surgery , pathology
The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom